Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ4Z6E)

Drug Name

ISORHAMNETIN Drug Info

Synonyms

Isorhamnetin; 480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5281654
ChEBI ID: CHEBI:6052
CAS Number: CAS 480-19-3
TTD Drug ID: DMQ4Z6E

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Plasmodium Enoyl-ACP reductase (Malaria fabI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[3]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[4]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[5]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[5]
Morin	DM2OGZ5	Discovery agent	N.A.	Investigative	[2]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[2]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[2]
Thiolactomycin	DMBAWDG	Malaria	1F40-1F45	Investigative	[3]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[2]
Diazaborines	DM5UFZX	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[2]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[2]
Kaempferol	DMHEMUB	Discovery agent	N.A.	Investigative	[2]
Morin	DM2OGZ5	Discovery agent	N.A.	Investigative	[2]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[2]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[2]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[7]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[2]
NADPH	DM75Q34	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Drug(s) Targeting Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PINOCEMBRIN	DM96VWD	N. A.	N. A.	Phase 2	[1]
Naringenin	DMHAZLM	N. A.	N. A.	Phase 1	[1]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[1]
Apigenin	DMI3491	Discovery agent	N.A.	Investigative	[1]
Kaempferol	DMHEMUB	Discovery agent	N.A.	Investigative	[1]
Acacetin	DMQOB0X	Discovery agent	N.A.	Investigative	[1]
TRISMETHOXYRESVERATROL	DM6USPC	Discovery agent	N.A.	Investigative	[9]
Galangin	DM5TQ2O	Discovery agent	N.A.	Investigative	[1]
CHRYSOERIOL	DM96ECL	Discovery agent	N.A.	Investigative	[1]
DIOSMETIN	DM4KXIM	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytochrome P450 1B1 (CYP1B1)	TTI84H7	CP1B1_HUMAN	Inhibitor	[1]
Plasmodium Enoyl-ACP reductase (Malaria fabI)	TTNX2CS	Q965D5_PLAFA	Inhibitor	[2]
Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)	TTBE4IR	Q965D6_PLAFA	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
2	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
3	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
4	Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
5	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6	Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
7	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
8	Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92.
9	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.